☆ 4.3 Editorial Material

The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)

Journal

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

Volume 9, Issue 6, Pages 283-292

Publisher

WILEY

DOI: 10.1111/cts.12429

Keywords

-

Categories

Medicine, Research & Experimental

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?

Severin Rodler, Andreas Jung, Philipp A. Greif, Katharina Ruehlmann, Maria Apfelbeck, Alexander Tamalunas, Alexander Kretschmer, Gerald B. Schulz, Bernadett Szabados, Christian Stief, Volker Heinemann, Christoph B. Westphalen, Jozefina Casuscelli

Summary: The aim of the study was to assess the feasibility and impact of routine NGS in personalized medicine for patients with genitourinary cancers. The results showed that NGS is increasingly feasible in clinical routine, with a growing number of tests performed and a decreasing turnaround time for therapy recommendations. However, challenges remain in terms of limited access to target agents for precision uro-oncology implementation.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer

Sushmaa Chandralekha Selvakumar, K. Auxzilia Preethi, Kehinde Ross, Deusdedit Tusubira, Mohd Wajid Ali Khan, Panagal Mani, Tentu Nageswara Rao, Durairaj Sekar

Summary: Personalized or precision medicine combines genetic information with phenotypic and environmental characteristics to tailor healthcare to individuals, enabled by cancer genome sequencing. The advantages of NGS, such as limited sample requirements and the development of biomarkers, have accelerated personalized medicine.

MOLECULAR CANCER (2022)

Add to Collection

Article Health Care Sciences & Services

Diagnosis of Sickle Cell Disease and HBB Haplotyping in the Era of Personalized Medicine: Role of Next Generation Sequencing

Adekunle Adekile, Nagihan Akbulut-Jeradi, Rasha Al Khaldi, Maria Jinky Fernandez, Jalaja Sukumaran

Summary: NGS technology was used to analyze the genotypes and haplotypes of HbSS and S beta-thal patients, revealing significant discordance between HPLC and NGS results, with a sensitivity of 79% for the identification of S beta-thal. Among the 13 beta-thal mutations detected, IVS-1 del25 and IVS-II-1 (G>A) were the most common.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Review Engineering, Biomedical

Next-generation personalized cranioplasty treatment

Bikramjit Basu, Jeyapriya Thimukonda Jegadeesan, Manish Baldia

Summary: Decompressive craniectomy (DC) is commonly used to treat various brain disorders, while cranioplasty surgery restores cranial symmetry and cosmetic outcomes. The manufacturing of patient-specific implants has shifted towards biomolecules and cellular-based methods. Despite advancements in 3D printing and image processing, the clinical procedure is time-consuming and costly. Therefore, automated implant fabrication using data-driven methods can accelerate the design and manufacturing of patient-specific cranial implants, providing predictable clinical outcomes.

ACTA BIOMATERIALIA (2022)

Add to Collection

Article Health Care Sciences & Services

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

Aya El Helali, Tai-Chung Lam, Elaine Yee-Ling Ko, David J. H. Shih, Chun Kau Chan, Charlene H. L. Wong, Jason W. H. Wong, Lydia W. T. Cheung, Johnny K. S. Lau, Anthony P. Y. Liu, Ann S. Y. Chan, Herbert H. Loong, Stephen Tak Sum Lam, Godfrey Chi-Fung Chan, Victor H. F. Lee, Kwok Keung Yuen, Wai-Tong Ng, Anne W. M. Lee, Edmond S. K. Ma

Summary: This study investigated the feasibility of the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong. The results showed that MTB-guided treatment positively impacted patients' overall survival, illustrating the applicability of next-generation sequencing comprehensive gene profiling (CGP) in real-world clinical practice.

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

Add to Collection

Article Oncology

Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers

Arnaud Bayle, Debora Basile, Simon Garinet, Bastien Rance, Pierre Laurent-Puig, Helene Blons, Julien Taieb, Geraldine Perkins

Summary: This study evaluated the role of NGS targeted panels in digestive oncology, showing that it allows for an exhaustive search for molecular abnormalities and provides patients with more opportunities for targeted therapies. Regular updates and further studies are needed for better analysis of prognostic factors.

CANCERS (2021)

Add to Collection

Review Health Care Sciences & Services

Next-Generation Examination, Diagnosis, and Personalized Medicine in Periodontal Disease

Takeshi Kikuchi, Jun-ichiro Hayashi, Akio Mitani

Summary: Periodontal disease is an infectious disease with a close relationship to lifestyle, and its treatment varies depending on individual patients. Precision medicine and personalized medicine offer more predictive treatment approaches, requiring a new diagnostic system and ongoing research on biomarkers, genetics, and oral bacteria complexity.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Smart pills and drug delivery devices enabling next generation oral dosage forms

Carmen Milian-Guimera, Reece Mccabe, Lasse Hojlund Eklund Thamdrup, Mahdi Ghavami, Anja Boisen

Summary: Oral dosage forms are the preferred solution for systemic treatment and prevention of diseases, but traditional forms face challenges. Research on novel formulation strategies for oral drug delivery has bloomed in the last decade to overcome these challenges, with approaches based on drug release and mucus interfacing showing promising results in personalized medicine and improved bioavailability.

JOURNAL OF CONTROLLED RELEASE (2023)

Add to Collection

Review Medical Laboratory Technology

Application of Next Generation Sequencing in Laboratory Medicine

Yiming Zhong, Feng Xu, Jinhua Wu, Jeffrey Schubert, Marilyn M. Li

Summary: This review discusses the rapid advancement of next-generation sequencing technology and its wide clinical applications in precision medicine, particularly in inherited diseases, oncology, and infectious diseases. It highlights the importance of NGS in clinical oncology, FDA-approved NGS panels, and the role of host microbiome in infectious diseases. The review also addresses the challenges and future prospects of clinical NGS tests.

ANNALS OF LABORATORY MEDICINE (2021)

Add to Collection

Article Oncology

Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies

Wencke Walter, Nicole Pfarr, Manja Meggendorfer, Philipp Jost, Torsten Haferlach, Wilko Weichert

Summary: Molecular diagnostics has played a crucial role in precision oncology and has undergone revolutionary developments in recent years. In most cases, it is no longer possible to select treatments for cancer patients without molecular characterization. However, there has been limited scientific research on preanalytical and analytical requirements, and standardization and quality assessment have played a marginal role in the field.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

3D Bioprinting for Next-Generation Personalized Medicine

Ethan Hau Yin Lam, Fengqing Yu, Sabrina Zhu, Zongjie Wang

Summary: In the past decade, personalized medicine has made significant progress in addressing patient-specific disease complexities and developing individualized treatment strategies. The emergence of 3D bioprinting has provided novel opportunities for personalized medicine, although current bioprinted constructs have limitations in achieving anatomically realistic organs with mature biological functions. This review discusses the principles and realizations of bioprinting, focusing on techniques such as extrusion printing and digital light processing (DLP). It also explores the applications of bioprinted constructs in regenerative medicine and drug discovery. Despite the challenges, bioprinting shows promise as an empowering technology to overcome critical obstacles in personalized medicine.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Immunology

Primary Immunodeficiencies in India: Molecular Diagnosis and the Role of Next-Generation Sequencing

Arun Kumar Arunachalam, Madhavi Maddali, Fouzia N. Aboobacker, Anu Korula, Biju George, Vikram Mathews, Eunice Sindhuvi Edison

Summary: This study characterized the clinical and genetic spectrum of PID patients in India, identifying BTK and IL12RB1 as the most common mutated genes, with autosomal recessive and X-linked recessive inheritance in 51.6% and 23.7% of patients, respectively. MSMD and IL12RB1 mutations were more common in this population compared to the Western world and the Middle East.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization

Valentina Angerilli, Francesca Galuppini, Fabio Pagni, Nicola Fusco, Umberto Malapelle, Matteo Fassan

Summary: The current practice of pathology is influenced by the increasing complexity of modern medicine, especially precision oncology, as well as major technological advancements. In the era of next-generation technologies, pathologists are responsible for integrating and interpreting morphologic and molecular information, delivering critical answers to diagnostic, prognostic, and predictive queries, and playing a prominent role in molecular tumor boards.

DIAGNOSTICS (2021)

Add to Collection

Article Microbiology

Comparing the significance of the utilization of next generation and third generation sequencing technologies in microbial metagenomics

Ilayda Akacin, Seymanur Ersoy, Osman Doluca, Mine Gungormusler

Summary: This review provides a comprehensive overview of recent literature on the utilization of TGS and NGS technologies in microbial metagenomics research. It discusses the advantages and limitations of these technologies and presents real-time examples of novel applications in clinical microbiology and public health, food and agriculture, energy and environment, arts and space.

MICROBIOLOGICAL RESEARCH (2022)

Add to Collection

Review Obstetrics & Gynecology

The role of next-generation sequencing in the investigation of ultrasound-identified fetal structural anomalies

M. D. Kilby

Summary: This paper reviews the role of NGS in investigating fetal malformations, emphasizing the importance of prospective case selection and informative pre-test counseling, as well as the crucial role of regulated laboratory sequencing and bioinformatic pathways in clinical practice.

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2021)

Add to Collection

Article Oncology

Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort

Isabelle Hardy-Leger, Cecile Charles, Marie Lange, Florence Joly, Pauline Roux, Aurelie Capel, Jean Petrucci, Olivier Rigal, Johan Le Fel, Laurence Vanlemmens, Sibille Everhard, Anne-Laure Martin, Ines Vaz Luis, Charles Coutant, Paul Cottu, Christelle Levy, Florence Lerebours, Fabrice Andre, Idlir Licaj, Sarah Dauchy

Summary: Cognitive complaints are more common in women with breast cancer than in healthy controls, with four distinct groups identified based on cognitive assessments before treatment. The groups with higher proportions of complaints showed more impairment in executive function, higher levels of anxiety, depression, fatigue, and lower quality of life.

PSYCHO-ONCOLOGY (2021)

Add to Collection

Article Oncology

A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

Julie Le Naour, Peng Liu, Liwei Zhao, Sandy Adjemian, Zsofia Sztupinszki, Julien Taieb, Claire Mulot, Aymeric Silvin, Charles-Antoine Dutertre, Florent Ginhoux, Allan Sauvat, Giulia Cerrato, Francesca Castoldi, Isabelle Martins, Gautier Stoll, Juliette Paillet, Khady Mangane, Cornelia Richter, Oliver Kepp, Maria Chiara Maiuri, Federico Pietrocola, Peter Vandenabeele, Fabrice Andre, Suzette Delaloge, Zoltan Szallasi, Pierre Laurent-Puig, Jessica Zucman-Rossi, Laurence Zitvogel, Jonathan G. Pol, Erika Vacchelli, Guido Kroemer

Summary: The interaction between ANXA1 released by dying cancer cells and FPR1 on dendritic cells is crucial for the immunogenicity of anthracycline-based chemotherapy. Strategies are needed to improve the anticancer immune response in individuals with loss-of-function alleles of FPR1. Immunotherapy using pIC can restore deficient chemotherapeutic responses in tumors lacking ANXA1, suggesting a personalized approach for compensating for FPR1 defects.

CANCER DISCOVERY (2021)

Add to Collection

Review Oncology

Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Mihaela Aldea, Fabrice Andre, Aurelien Marabelle, Semih Dogan, Fabrice Barlesi, Jean-Charles Soria

Summary: Resistance to anticancer therapies can be classified into primary and secondary resistance, primarily influenced by target dependency and cellular adaptability. Immunotherapy resistance is often driven by tumor-host-microenvironment interactions, while targeted therapy resistance is typically driven by alterations in targets.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, Anne-Laure Martin, Sibille Everhard, Charles Coutant, Paul Cottu, Anne Lesur, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio

Summary: The study found that the long-term use of G-CSF in early-stage breast cancer patients did not show significant associations with PROs and hematologic toxicity. Patients receiving G-CSF had slightly worse PROs at year-4, but the differences were of trivial clinical significance. There were no major differences in leukocyte or platelet count over time.

BREAST (2021)

Add to Collection

Editorial Material Oncology

Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

K. S. Saini, I. M. Svane, M. Juan, F. Barlesi, F. Andre

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review

C. Corti, G. Antonarelli, F. Scotte, J. P. Spano, J. Barriere, J. M. Michot, F. Andre, G. Curigliano

Summary: This systematic review investigates the immunogenicity of COVID-19 vaccines in patients with cancer (PsC). The results show that vaccination against COVID-19 is generally safe and immunogenic for PsC. However, the seroconversion rate in PsC is lower, lagged, or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are at the highest risk of poor seroconversion.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer

G. Middleton, H. Robbins, F. Andre, C. Swanton

Summary: Based on the results from several platform studies, it has been concluded that genotype-matched therapy is effective for cancer patients, but there are still challenges in combination therapy. Precision medicine holds great promise in cancer treatment, but more accurate models are needed to capture the genomic complexity of human diseases.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A. Mittendorf, Hope Rugo, Sara M. Tolaney, Giampaolo Bianchini, Fabrice Andre, Giuseppe Curigliano

Summary: Advancements in the treatment of localized triple negative breast cancer (TNBC) are reshaping the landscape of this disease, with the addition of pembrolizumab showing significant improvement in survival. However, there are still questions regarding patient selection, integration with other treatments, and minimizing side effects.

NPJ BREAST CANCER (2022)

Add to Collection

Article Oncology

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

Sherene Loi, Roberto Salgado, Sylvia Adams, Giancarlo Pruneri, Prudence A. Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Damien Drubay, Jerome Lemonnier, Christos Sotiriou, Pirkko Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, Martine Piccart, Elvire Roblin, Stefan Michiels

Summary: The importance of integrating biomarkers such as TILs into the TNM staging system for TNBC has been emphasized in the AJCC 8th Edition. Studies show that TILs can significantly influence the traditional pathological staging, suggesting that considering TILs in addition to stage can lead to better outcomes for TNBC patients.

NPJ BREAST CANCER (2022)

Add to Collection

Article Health Care Sciences & Services

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe

Denis Horgan, Giuseppe Curigliano, Olaf Riess, Paul Hofman, Reinhard Buettner, Pierfranco Conte, Tanja Cufer, William M. Gallagher, Nadia Georges, Keith Kerr, Frederique Penault-Llorca, Ken Mastris, Carla Pinto, Jan Van Meerbeeck, Elisabetta Munzone, Marlene Thomas, Sonia Ujupan, Gilad W. Vainer, Janna-Lisa Velthaus, Fabrice Andre

Summary: Next-generation sequencing (NGS) has the potential to revolutionize cancer treatment with its personalized approach. However, the implementation of NGS in Europe varies, highlighting the need for collaboration among stakeholders. To address this issue, the European Alliance for Personalised Medicine (EAPM) established expert panels consisting of key stakeholders from 10 European countries. The panels identified challenges related to NGS demand and supply, and made recommendations for multi-stakeholder collaboration to improve patient care.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice Andre, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O'Shaughnessy

Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Frederique Berger, Margaux Marce, Suzette Delaloge, Anne-Claire Hardy-Bessard, Thomas Bachelot, Ivan Bieche, Anne Pradines, Thibault De La Motte Rouge, Jean-Luc Canon, Fabrice Andre, Laurent Arnould, Florian Clatot, Jerome Lemonnier, Sandrine Marques, Francois-Clement Bidard

Summary: This study aims to prove the clinical efficacy of periodic monitoring for emerging or rise of ESR1 mutations in ctDNA to trigger an early change from AI plus palbociclib to fulvestrant plus palbociclib treatment while assessing global safety.

BMJ OPEN (2022)

Add to Collection

Meeting Abstract Oncology

Preclinical evaluation of a PKC and MET inhibitor combination in metastatic uveal melanoma.

Marie-Claire Wagle, Nandini Ravindran, Divya Pankajakshan, Mark Lackner, Zineb Mounir

CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

MAT2A inhibitor, IDE397, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts.

Marcus M. Fischer, Neil Bhola, John Faulhaber, Yevgeniy Freyman, Bing Yao, Zineb Mounir, Mark R. Lackner, Claire Neilan

CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Hope Rugo, Antonio Llombart-Cussac, Fabrice Andre, Mark E. Robson, Shigehira Saji, Nadia Harbeck, Peter Schmid, David Cescon, Jin Seok Ahn, Rita Nanda, Li Fan, Jaime Alberto Mejia, Vassiliki Karantza, Aditya Bardia

CANCER RESEARCH (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.